A Novel Depsipeptide Produced by Paenibacillus alvei 32 Isolated from a Cystic fibrosis Patient
- 194 Downloads
The important viscosity of the respiratory tract mucus of Cystic fibrosis (CF) patients impairs the mucociliary transport system and allows the growth of numerous micro-organisms. Among them, Pseudomonas aeruginosa and Staphylococcus aureus are known to be responsible for pulmonary infections. We imagined that CF microflora could also harbour micro-organisms naturally equipped to compete with these pathogens. A method was developed to recover these antibiotic-producing strains within 20 CF sputum. Using this approach, we have isolated an unusual Gram-positive bacterium identified as Paenibacillus alvei by Api galleries and 16S rRNA gene sequence analysis. This strain has inhibited the growth of P. aeruginosa, S. aureus and Klebsiella pneumoniae, in co-cultures. A liquid mineral medium named MODT50 was designed and optimised for the production and the recovery of the antimicrobial compounds. The supernatant has inhibited the growth of all Gram-positive strains tested, even Methicillin-resistant S. aureus. One antimicrobial compound with a peptide structure (mainly active against S. aureus, Micrococcus luteus, and Pseudomonas stutzeri) has been purified and characterised by liquid chromatography-mass spectrometry. The new active molecule (m/z 786.6) named depsipeptide l possesses a 15-guanidino-3-hydroxypentadecanoic acid side chain (m/z 298) linked on a cyclic part of four amino acids residues (Ser, two Leu/Ile, Arg). This work reports for the first time the production of such a molecule by a P. alvei strain in a mineral medium. The CF lung microflora might represent a valuable source for the discovery of new antimicrobial-producing strains.
KeywordsPaenibacillus alvei Antimicrobial-peptide Cystic fibrosis Depsipeptide Fusaricidin
This study was supported by “l’Association Vaincre la Mucoviscidose”. The authors are indebted to the patients with CF from the CRCM of Nantes (France). We are grateful to Monique Bordes (CCA, La Rochelle, France) for her help with electron microscopy. We thank the Pr. Michael Givskov (Technical University of Denmark) for providing the PA01 lasB-gfp(ASV) strain. We thank Mr. Thomas Marsh for English corrections.
- 8.Coudron PE, Payne JM, Markowitz SM (1991) Pneumonia and empyema infection associated with a Bacillus species that resembles B. alvei. J Clin Microbiol 29:1777–1779Google Scholar
- 15.Geoffroy C, Mengaud J, Alouf JE, Cossart P (1990) Alveolysin, the thiol-activated toxin of Bacillus alvei, is homologous to listeriolysin O, perfringolysin O, pneumolysin, and streptolysin O and contains a single cysteine. J Bacteriol 12:7301–7305Google Scholar
- 29.Reboli AC, Bryan CS, Farrar WE (1989) Bacteremia and infection of a hip prosthesis caused by Bacillus alvei. J Clin Microbiol 27:1395–1396Google Scholar
- 30.Reynaldi FJ, De Giusti MR, Alippi AM (2004) Inhibition of the growth of Ascosphaera apis by Bacillus and Paenibacillus strains isolated from honey. Rev Argent Microbiol 36:52–55Google Scholar
- 31.Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Kehagia V, Connett GJ, Bruce KD (2006) Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with Cystic fibrosis. J Clin Microbiol 44:2601–2604CrossRefGoogle Scholar